Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

How Aviva plc (AV) Measures Up As a GARP Investment

LONDON — A popular way to dig out reasonably priced stocks with robust growth potential is through the “Growth At A Reasonable Price,” or GARP, strategy. This theory uses the price-to-earnings to growth (PEG) ratio to show how a share’s price weighs up in relation to its near-term growth prospects — a reading below 1 is generally considered decent value for money.

Aviva Plc

Today I am looking at Aviva plc (LON:AV) to see how it measures up.

What are Aviva’s earnings expected to do?

2013 2014
EPS Growth n/a 9%
P/E Ratio 8 7.4
PEG Ratio n/a 0.9

Source: Digital Look.

Aviva plc (LON:AV) does not boast a valid earnings per share (EPS) growth figure in 2013, although this is a mathematical issue. EPS forecasts of 42.1 pence for this year compare with losses per share of 15.2 pence in 2012. Growth is expected to moderate to 45.7 pence next year, however.

The insurer fails to provide a valid PEG rating for this year owing to this projected earnings swing, although 2014’s value falls within the bargain benchmark of 1. As well, the company’s price-to-earnings (P/E) ratio registers at below 10 for the next two years — a value below 1 is considered stunning value for money.

Does Aviva provide decent value against its rivals?

FTSE 100 Life Insurance
Prospective P/E Ratio 14.8 12.8
Prospective PEG Ratio 4.5 4.5

Source: Digital Look.

Both the FTSE 100 and life insurance sectors can provide valid forward PEG ratios, albeit comfortably above the value threshold of 1, unlike Aviva plc (LON:AV). Still, the life insurance company’s vastly better P/E rating illustrates its value as a decent value stock.

Aviva plc (LON:AV)’s earnings snapback this year, combined with cheap PEG rating in 2014, mark it out as a decent GARP selection on face value, according to City analysts. However, for some investors the company may still represent a risky pick owing to the steps it still has to take as part of its restructuring plan.

Getting better but still a long road ahead
In the last financial year, Aviva plc (LON:AV) slashed the final dividend 44% in a bid to cut leverage and boost retained earnings. It also announced that the interim payout in the current year would suffer a similar markdown. This prompted interest in the insurer to drop as investors weighed the subsequent anticipated earnings improvement against future dividend uncertainty.

The company’s May interims gave reason for cheer as new business value rose 18% in January-March to £191 million, helped by a 33% increase in new business from its critical U.K. operations. However, enduring weakness on the continent weighed on the results, with business in Spain falling 67% and Italian business falling 56% from the same 2012 period.

The company still has a long slog ahead in terms of cost reduction, even though operational costs fell 10% in quarter one. Although Aviva plc (LON:AV) is undoubtedly making progress with its turnaround plan, mixed results across its international operations, rising competition at home, and patchy combined ratio results across the group, mean that I would like to see further signs of improvement before selecting the firm as a stable growth stock.

The article How Aviva Measures Up As a GARP Investment originally appeared on and is written by Royston Wild.

Royston does not own shares in Aviva. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!